Ceftriaxone in the treatment of Lyme neuroborreliosis.
In an open non-comparative clinical trial with the aim of evaluating the clinical efficacy and safety of a 14 day course of 2 g ceftriaxone once daily, 46 patients with neuroborreliosis were entered at the Infectious Diseases Teaching Hospital in Prague 8. In 39 patients the diagnosis was early Lyme neuroborreliosis. Seven patients suffered from late stage disease. Clinical results were 30% of patients cured at the end of treatment and 85% after 9 months in early stage disease. In late stage disease two patients out of seven were cured and four had improved after 12 months. One patient died because of cardiac infarction. In no patient had treatment to be discontinued because of adverse reactions to antibiotics.
Rohácová
H
H
Hospital of Infectious Diseases, Charles University, Prague, Czech Republic.
Hancil
J
J
Hulinská
D
D
Mailer
H
H
Havlík
J
J
D000328:Adult; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D015748:Borrelia burgdorferi Group / Q000276:immunology / Q000302:isolation & purification / Q000648:ultrastructure; D002443:Ceftriaxone / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008193:Lyme Disease / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D008297:Male; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D013987:Ticks; D016896:Treatment Outcome
D000907:Antibodies, Bacterial; D002443:Ceftriaxone